Here’s why Palantir’s stock is down despite a ‘bombastic’ quarter
-
A deceleration in U.S. commercial contract growth gave some Wall Street
analysts pause despite Palantir’s earnings beat.
4 hours ago



Joel Fuhrman MD: Nearly Everyone Gets Cancer: http://youtu.be/sGrmA8iylds via @youtube
ReplyDelete